Myeloid cell leukemia 1 mRNA 3' untranslated region (MCL1 mRNA 3'UTR)

The Myeloid cell leukemia 1 (MCL1) mRNA 3' untranslated region (3'UTR) is a pivotal regulatory segment of the MCL1 transcript that controls the expression of the MCL1 protein, a potent anti-apoptotic member of the BCL-2 family (UniProt P92431). This region contains multiple binding sites for microRNAs, such as the miR-29 and miR-101 families, and various RNA-binding proteins that dictate mRNA stability and translational efficiency (Mott et al., 2007, Nature). In many cancers, the dysregulation of these regulatory interactions leads to the overexpression of MCL1, which promotes tumor cell survival and confers resistance to conventional chemotherapies and BH3 mimetics (Belmar & Fesik, 2015, Pharmacology & Therapeutics). Therapeutic strategies targeting the MCL1 mRNA 3'UTR, including antisense oligonucleotides and microRNA-based therapies, aim to reduce MCL1 protein levels to restore apoptotic sensitivity in malignant cells. However, because MCL1 is also critical for the survival of essential normal tissues like the heart and liver, targeting its expression requires precise delivery or dosing to avoid systemic toxicity (Thomas et al., 2013, Genes & Development).

Other names

MCL-1 3'UTRMyeloid cell leukemia sequence 1 3'UTRMCL1 3-prime untranslated regionMCL1 mRNA 3-prime UTR

Drugs targeting the MCL1 mRNA 3'UTR typically function by promoting mRNA degradation via RNase H-mediated cleavage (for ASOs) or the RNA-induced silencing complex (RISC) pathway (for microRNA mimics and siRNAs), or by sterically blocking the binding of stabilizing RNA-binding proteins, ultimately leading to reduced translation of the anti-apoptotic MCL1 protein (Mott et al., 2007, Nature; Zhang et al., 2011, FEBS Letters).